Malignant hypertension laboratory findings

Malignant hypertension Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Malignant hypertension from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Malignant hypertension laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Malignant hypertension laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Malignant hypertension laboratory findings
CDC on Malignant hypertension laboratory findings
Malignant hypertension laboratory findings in the news
Blogs on Malignant hypertension laboratory findings
Directions to Hospitals Treating Malignant hypertension
Risk calculators and risk factors for Malignant hypertension laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Laboratory Findings

• Complete blood count
• Electrolytes

• Coagulation profile

• Urinalysis

• Cardiac enzymes

• urinary catecholamines

• Thyroid-stimulating hormone (TSH)

• 24-hour urine collection for vanillylmandelic acid (VMA) and catecholamines.
• BUN, creatinine

Urinalysis may reveal

• Proteinuria

• Microscopic hematuria

• RBC or hyaline casts.

In patients with hyperaldosteronism (a secondary cause of hypertension), aldosterone promotes renal potassium wasting, resulting in low serum potassium.

References

Template:WikiDoc Sources